Under construction – not a live service
Sign in
Enrolling by invitationPhase 2/3

Long-term safety study of aficamten in adults with hypertrophic cardiomyopathy

Studies long-term safety of aficamten in adults with a heart thickening disease.

Plain-language title generated from the registry record
Registry title: Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Key facts

Where
Anchorage, Ann Arbor, Atlanta, Birmingham, Boston, Burlington, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Dallas, Detroit, Durham, Falls Church, Fayetteville, Fort Lauderdale, Greenville, Honolulu, Houston, Iowa City, Kansas City, La Jolla, Los Angeles, Manhasset, Milwaukee, Minneapolis, Morgantown, Morristown, Murray, Nashville, New Haven, New York, Philadelphia, Phoenix, Pittsburgh, Portland, Rochester, Salt Lake City, San Francisco, Seattle, Tulsa, Valhalla, and Washington D.C., United StatesSee the 57 sites
Phase
Phase 2/3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Source: NCT04848506, who can take part

Where in United States

  • Alaska Heart and Vascular InstituteAnchorage, United StatesNo longer taking part
  • Michigan Medicine - University of MichiganAnn Arbor, United StatesNo longer taking part
  • University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Center)Ann Arbor, United StatesNo longer taking part
  • Emory ClinicAtlanta, United StatesNo longer taking part
  • University of Alabama at BirminghamBirmingham, United StatesNo longer taking part
  • Brigham and Women's HospitalBoston, United StatesNo longer taking part
  • Massachusetts General HospitalBoston, United StatesNo longer taking part
  • Lahey Hospital & Medical CenterBurlington, United StatesNo longer taking part
  • Medical University of South CarolinaCharleston, United StatesNo longer taking part
  • Sanger Heart & Vascular Institute, Atrium HealthCharlotte, United StatesNo longer taking part
  • University of Virginia Health System University HospitalCharlottesville, United StatesNo longer taking part
  • Northwestern UniversityChicago, United StatesNo longer taking part
  • The Linder Research Center at The Christ HospitalCincinnati, United StatesNo longer taking part
  • Cleveland ClinicCleveland, United StatesNo longer taking part
  • University Hospitals Cleveland Medical Center*Cleveland, United StatesNo longer taking part
  • The University of Texas Southwestern Medical Center at DallasDallas, United StatesNo longer taking part
  • Henry Ford HospitalDetroit, United StatesNo longer taking part
  • Duke Cardiology at SouthpointDurham, United StatesNo longer taking part
  • Inova Health Care ServicesFalls Church, United StatesNo longer taking part
  • Piedmont Fayette HospitalFayetteville, United StatesNo longer taking part
  • Holy Cross Hospital / Cardiology AssociatesFort Lauderdale, United StatesNo longer taking part
  • Greenville Memorial HospitalGreenville, United StatesNo longer taking part
  • The Queen's Medical CenterHonolulu, United StatesNo longer taking part
  • CHI St. Luke's Health Baylor College of Medicine Medical CenterHouston, United StatesNo longer taking part
  • Houston Methodist HospitalHouston, United StatesNo longer taking part
  • The University of Iowa Hospitals & ClinicsIowa City, United StatesNo longer taking part
  • Saint Luke's Hospital of Kansas CityKansas City, United StatesNo longer taking part
  • The University of Kansas Medical CenterKansas City, United StatesNo longer taking part
  • UC San Diego Health-Sulpizio Cardiovascular CenterLa Jolla, United StatesNo longer taking part
  • Cedar Sinai Medical CenterLos Angeles, United StatesNo longer taking part
  • Cedars-Sinai Medical Center (Smidt Heart Institute)Los Angeles, United StatesNo longer taking part
  • UCLA Health System - UCLA Cardiovascular CenterLos Angeles, United StatesNo longer taking part
  • Northwell Health North Shore University HospitalManhasset, United StatesNo longer taking part
  • Aurora St. Luke's Medical CenterMilwaukee, United StatesNo longer taking part
  • University of MinnesotaMinneapolis, United StatesNo longer taking part
  • WVUMedicineMorgantown, United StatesNo longer taking part
  • Morristown Medical CenterMorristown, United StatesNo longer taking part
  • Intermountain Medical CenterMurray, United StatesNo longer taking part
  • Ascension Saint Thomas Heart WestNashville, United StatesNo longer taking part
  • Vanderbilt University Medical CenterNashville, United StatesNo longer taking part
  • Yale New Haven HospitalNew Haven, United StatesNo longer taking part
  • Columbia University Medical Center/New York-Presbyterian HospitalNew York, United StatesNo longer taking part
  • Mount Sinai HospitalNew York, United StatesNo longer taking part
  • NYU Langone HealthNew York, United StatesNo longer taking part
  • Weill Cornell MedicineNew York, United StatesNo longer taking part
  • Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)Philadelphia, United StatesNo longer taking part
  • Mayo Clinic Building-PhoenixPhoenix, United StatesNo longer taking part
  • UPMC PresbyterianPittsburgh, United StatesNo longer taking part
  • Oregon Health Science UniversityPortland, United StatesNo longer taking part
  • Providence St. Vincent Medical CenterPortland, United StatesNo longer taking part
  • Mayo ClinicRochester, United StatesNo longer taking part
  • University Of Utah HealthSalt Lake City, United StatesNo longer taking part
  • UCSF Medical CenterSan Francisco, United StatesNo longer taking part
  • Virginia Mason Medical CenterSeattle, United StatesNo longer taking part
  • Ascension St. John Clinical Research InstituteTulsa, United StatesNo longer taking part
  • Westchester Medical CenterValhalla, United StatesNo longer taking part
  • MedStar Washington Hospital CenterWashington D.C., United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Cytokinetics
Trial code
NCT04848506EU 2023-508963-58-00
Record updated
13 October 2026
Original description
The purpose of this study is to collect long-term safety and tolerability data for aficamten.Read full original descriptionShow less

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

The purpose of this study is to collect long-term safety and tolerability data for aficamten.

Inclusion: Completion of a Cytokinetics trial investigating aficamten; LVEF ≥ 55% at the Screening Visit.

Exclusion: Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor; Has participated in another investigational device or drug study or received an investigational device or drug < 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted; Since completion of a previous trial of aficamten has:; Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) < 30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) < 100 bpm and/or rhythm is stable > 30 days; Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation); History of implantable ICD placement within 30 days prior to screening; Had a confirmed LVEF < 40% with an associated dose interruption during participation in a prior study with aficamten.

ClinicalTrials.gov NCT04848506 · EU CTIS 2023-508963-58-00